Journey & Honors

当前位置: > Company > Journey & Honors

Journey & Honors

Major Milestones

2010

    •  Asieris Pharmaceuticals was founded and registered in the China Medical City, Taizhou, Jiangsu Province.

2012

    •  A Pre-IND meeting was held with the US FDA; the FDA issued written concurrence of Asieris' proposed phase II clinical protocol to investigate the effects of APL-1202 in non-muscle-invasive bladder cancer patients;

    •  Asieris received “Clinical Trail Acceptance Notice from the China FDA for conducting a Phase 2 clinical trial in non-muscle invasive bladder cancer patients.

2013

    •  Asieris received the Clinical Trial Approval (CTA) from the China FDA for conducting the Phase 2 clinical trial in non-muscle invasive bladder cancer patients.

2014

    •  Wanchuan Pharmaceutical and Taifu Funds invest in Asieris.

2015

    •  The APL-1202 Phase II clinical trial in China completed itsenrollment 

2016

    •  Invited to attend the European Association of Urology Munich Conference in Germany, where the interim results from the APL-1202 Phase II clinical trial in China was presented and was highly recognized by experts around the world;

    •  Opened the Shanghai Office for establishing a team of experts;

    •  Reached agreement with the China FDA on the APL-1202 Pivotal Trail Protocol.

2017

    •  Launched the APL-1202 Pivotal Trial in China;

    •  Signed the APL-1202 MAH Strategic Partnership Agreement with Wisdom Pharmaceutical;

    •  Completed Round B fund raising led by Lapam Capital, and jointly invested by Kaitai Capital, Qihang Funds, Phoenix Investment, and other investors.

2018

    •  Established the Shanghai R&D Center and launched the New Drug R&D Discovery Platform;

    •  Held a Pre-IND meeting with FDA; successfully submitted a US IND and received permission from the US FDA to initiate the clinical trial;

    •  Signed the Collaboration Agreement with the Suzhou manufacturing site of Jiangsu Wuzhong Pharmaceutical Group Corporation;

    •  Opened the Beijing Office.

2019
    •  APL-1202 Phase III clinical trial in China completed its enrollment 
    •  Signed license agreement for world-wide development and commercialization of Cevira® with Photocure


Our Honors

2012

    •  Awarded an “International Technology Transfer and Joint R&D Project” grant and a “Science and Technology Driven Social Development Projects”  funding support by the Science and Technology Department of Jiangsu Province.

2015

    •  Asieris' APL-1202 awarded as recipient of the "National 12th Five-Year Major New Drug Innovation Program";

    •  Selected as one of the “Small to Mid-sized Scientific and Technological Enterprises” in Jiangsu Province;

2017

    •  APL-1202 awarded as one of the "National 13th Five-Year Major New Drug Innovation Programs".

    •  Selected as one of the“ Small to Mid-sized Scientific and Technological Enterprises”of China;

2018

    •  APL-1501 awarded as recipient of the "National 13th Five-Year Major New Drug Innovation Program";

    •  Selected as one of the“ Small to Mid-sized Scientific and Technological Enterprises”of China;

    •  Best poster award at the 113th American Urological Association (AUA) Annual Meeting for the pre-clinical study on the effect of the APL-1202 and PD-1 antibodycombination for the treatment of prostate cancer.

2019
    •  Dr. Yijun Deng, Vice President of Drug Discovery of Asieris was selected into “113 Medical Talents Program” of CMC
    •  Cevira® won Medical Device Innovation of Fierce Innovation Awards – Life Sciences Edition 2019


返回顶部